Premium
PROPHYLACTIC 1α‐HYDROXYVITAMIN D 3 THERAPY IN HAEMODIALYSIS PATIENTS
Author(s) -
WALKER G. S.,
PEACOCK M.,
AARON J.,
ROBINSON P. J. A.,
DAVISON A. M.
Publication year - 1977
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1977.tb03372.x
Subject(s) - medicine , parathyroid hormone , alkaline phosphatase , endocrinology , calcification , dialysis therapy , dialysis , microgram , hemodialysis , vitamin d and neurology , calcium , urology , chemistry , enzyme , biochemistry , in vitro
SUMMARY Twenty‐seven patients starting regular haemodialysis were treated with a 1 μ g daily dose of l α‐hydroxyvitamin D 3 and concurrent aluminium hydroxide therapy to prevent hyperphosphataemia. There was an increase in plasma calcium, but no significant improvement in plasma alkaline phosphatase activity or parathyroid hormone levels. Metastatic calcification progressed but was never a severe clinical problem. Quantitative bone histology showed a significant decrease in resorptive surfaces confirmed radiologically, but there was no significant decrease in forming surfaces. The expected increase in forming surfaces with length of dialysis was however prevented.